Pyridines

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Wednesday, June 9, 2021 - 3:31am

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Key Points: 
  • TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
  • Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
  • Eisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy

Monday, June 7, 2021 - 6:00am

Addex is anticipating multiple clinical study catalysts during 2021.

Key Points: 
  • Addex is anticipating multiple clinical study catalysts during 2021.
  • The first, starting with this epilepsy study, illustrates the continued commitment of our long-time collaboration partner Janssen Pharmaceuticals, Inc. to this program and to pioneering novel ways to help epilepsy patients.
  • Data from the study are expected in Q3 2022, said Tim Dyer, CEO of Addex.
  • The primary objective of the study is to evaluate the efficacy of JNJ-40411813 (ADX71149) in combination with levetiracetam using a time-to-event endpoint.

Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting

Friday, June 4, 2021 - 2:03pm

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase III ExteNET trial assessing the impact of neratinib treatment duration on overall survival (OS) in patients with early stage HER2-positive breast cancer at the virtual 2021 ASCO Annual Meeting.

Key Points: 
  • Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase III ExteNET trial assessing the impact of neratinib treatment duration on overall survival (OS) in patients with early stage HER2-positive breast cancer at the virtual 2021 ASCO Annual Meeting.
  • ExteNET was a multicenter, randomized, double-blind, Phase III trial of 2,840 HER2-positive early stage breast cancer patients who received neratinib after neoadjuvant and/or adjuvant therapy with chemotherapy and trastuzumab-based treatment.
  • These descriptive findings suggest that overall survival in patients with early stage HER2-positive breast cancer patients is improved upon completion of neratinib extended adjuvant therapy.
  • HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death.

2021 Global Triclopyr (CAS 55335-06-3) Market Research Report - Downstream Industry Trends - ResearchAndMarkets.com

Tuesday, May 25, 2021 - 4:15pm

The "Triclopyr (CAS 55335-06-3) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Triclopyr (CAS 55335-06-3) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Triclopyr.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Triclopyr global market report key points:

Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis

Friday, May 21, 2021 - 3:10pm

In the KX01-AK-003 study, complete clearance was observed in 44% of the patients treated with tirbanibulin versus 5% for vehicle-treated groups.

Key Points: 
  • In the KX01-AK-003 study, complete clearance was observed in 44% of the patients treated with tirbanibulin versus 5% for vehicle-treated groups.
  • The approval of Klisyri (tirbanibulin) is expected in approximately 60 days and its launch in Europe could take place in late 2021.
  • Concerning other territories, Almirall submitted for a marketing authorisation in Switzerland in Q4 2020 and the dossier is currently under review by Swissmedic.
  • The company will also submit in Great Britain via the European Commission Decision Reliance Procedure.\nKlisyri (tirbanibulin) is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Friday, May 21, 2021 - 12:01pm

b'DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.\nNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.

Key Points: 
  • b'DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.\nNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA\xc2\xae (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO\xe2\x84\xa2 (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO\xc2\xae (tedizolid phosphate) in the United States and certain of its territories.\n'

AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma

Wednesday, May 19, 2021 - 10:02pm

\xe2\x80\x9cWe were also pleased to see efficacy advantages relative to sorafenib were maintained or improved with longer follow-up.

Key Points: 
  • \xe2\x80\x9cWe were also pleased to see efficacy advantages relative to sorafenib were maintained or improved with longer follow-up.
  • Additional analyses and long-term follow up results from the TIVO-3 study to be presented at the 2021 ASCO Annual Meeting include:\nDurability of Response and Updated Overall Survival.
  • It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment

Wednesday, May 19, 2021 - 4:24pm

Under the IND, Propella plans to initiate an open-label, phase 1/2a clinical study in June 2021.

Key Points: 
  • Under the IND, Propella plans to initiate an open-label, phase 1/2a clinical study in June 2021.
  • "We have strong preclinical data, and we\'re excited to be initiating a first-in-human trial.
  • The acetate prodrug of abiraterone is the current standard of care for advanced prostate cancer.
  • "\nToday, Propella also announced the appointment of Brendan Griffin to its leadership team asthe company\'s Chief Financial Officer(CFO).

Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

Monday, May 17, 2021 - 10:15pm

The purpose of this study is to determine the dose we will take into Phase 3 trials in 2022.

Key Points: 
  • The purpose of this study is to determine the dose we will take into Phase 3 trials in 2022.
  • As a reminder, this new formulation is expected to address the previous GI-related side effects associated with its oral administration.
  • The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need.
  • The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

Trevena to Release First Quarter 2021 Financial Results on May 6, 2021

Wednesday, May 5, 2021 - 12:00pm

b'The webcast should be accessed 15 minutes prior to the conference call start time.

Key Points: 
  • b'The webcast should be accessed 15 minutes prior to the conference call start time.
  • A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the company\xe2\x80\x99s website.\nTrevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • The Company has one approved product in the United States, OLINVYK\xe2\x84\xa2 (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
  • The Company\xe2\x80\x99s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for epilepsy and chronic neuropathic pain, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.\n'